METHOD AND GENETIC SIGNATURE FOR DETECTING INCREASED TUMOR MUTATIONAL BURDEN
The field of the invention generally relates to cancer, including methods for diagnosing, prognosing, and treating cancer. In particular, the field of the invention relates to novel signatures of unique sets of point mutations involving a change of a cytosine or a guanidine, and methods, systems, and components thereof based upon the novel signature for identifying tumor samples having increased tumor mutational burden (TMB). Both the signatures and the methods, systems, and components thereof may be utilized for identifying cancer patients, microsatellite stable-cancer patients in particular, who will effectively respond to immune checkpoint blockade therapy.
1 .- 27 . (canceled)
28 . A composition comprising:
primer pairs configured for the amplification of a plurality of different target sequences in a subject nucleic acid sample, wherein the target sequences comprise at least a subset of the loci listed in Table 1.
29 . The composition of claim 28 , further comprising:
reagents for sequencing amplicons generated by the primer pairs.
30 . The composition of claim 28 , comprising a cartridge, wherein the primer pairs are within the cartridge.
31 . The composition of claim 29 , comprising a cartridge, wherein the primer pairs and reagents for sequencing amplicons are within the cartridge.
32 . The composition of claim 28 , further comprising:
primer pairs configured for amplification of at least a portion of the catalytic subunit of polymerase ε (POLE) gene sequence.
33 . A composition comprising:
a panel, the panel comprising a plurality of nucleic acid probes, the probes optionally linked to a solid support, wherein the nucleic acids probes hybridize to a plurality of target sequence, the target sequences comprising at least a subset of loci listed in Table 1.
34 . The composition of claim 34 , wherein the composition comprises a cartridge, wherein the probes are within the cartridge.
34 . The composition of claim 33 , further comprising at least one POLE nucleic acid probe, optionally linked to a solid support, wherein the at least one POLE nucleic acid probe hybridize to at least a portion of the POLE gene sequence.
35 . A method comprising:
(a) contacting a patient sample nucleic acid sample with the composition of claim 1 ;
(b) amplifying the nucleic acid to generate amplicons;
(c) sequencing the amplicons to generate sequence data; and
(d) analyzing the sequence data to identify amplicons comprising a mutation listed in Table 1.
36 . The method of claim 35 , wherein the method is performed in a cartridge.